PharmaBoardroom

Novo Nordisk Switzerland’s Mads Stoustrup introduces the affiliate’s remarkable process on bringing innovative diabetes and obesity treatments to…

In a wide-ranging interview, Henrik Asmussen outlines his priorities for Amgen’s important Swiss affiliate, market access and pricing challenges,…

While Switzerland has Europe's second-highest proportion of women in the workforce, it trails global standards on gender diversity in boardrooms and…

Pfizer Switzerland’s Sabine Bruckner discusses Switzerland’s historic and continuing importance to Pfizer, vaccine development and uptake, and the…

Alfasigma Switzerland’s Dr Tytus Litynski introduces the Italian firm’s diversified portfolio of both Rx drugs and food supplements in…

Intergenerika’s Dr Axel B. Müller makes an impassioned case against the introduction of a reference pricing system in Switzerland, arguing that it…

Biogen Switzerland’s Dr Katharina Gasser outlines how the company’s 100 percent commitment to neuroscience helps it to stand apart, why…

Urs Vögeli, managing director for Janssen Switzerland, outlines the importance of the Swiss operations to Janssen, his interesting career journey,…

The USA is now Switzerland’s biggest export market and in 2019 Switzerland exported more to the US than to France, Italy, the UK and Austria…

Switzerland, rightly regarded as one of the world’s most innovative nations, risks damaging its reputation if innovative new medicines continue to…

scienceindustries’ Stephan Mumenthaler outlines the business-friendly regulation necessary to maintain Swiss life sciences’ competitive edge, how…

Axel Steiger, CEO and CFO for Bayer Switzerland, outlines the importance of the Swiss operations as one of the key global hubs for Bayer, his…